Key facts
- It has raised $10.1M.
- Notable investors include LetsVenture Technologies, Ashish Kacholia, JITO Incubation & Innovation Foundation, Chockalingam Valliappa, Dominor — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Epigeneres
- ·The full record, as it builds
Funding rounds
No funding rounds for Epigeneres are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epigeneres
Developer of advanced gene therapeutics intended for the treatment and prevention of medical conditions like cancer and diseases of aging. The company makes molecular medicines and nutrigenomic formulations and has co-developed, along with being the sole licensee of cancer prognostic and diagnostic technology, providing medical professionals with tools to diagnose and treat cancer and diseases related to aging.
- Sector
- Healthcare
- HQ
- Mumbai, India
- Founded
- 2012
- Employees
- 82
- Website
- epigeneres.com/
- Ownership
- Privately Held (backing)
Epigeneres doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epigeneres shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epigeneres in its N-PORT filings yet. We sweep new filings monthly.